AstraZeneca
Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect
Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls
AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge
AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion
Spotlight On: Big Pharma’s Big Bets on In Vivo Cell Therapy
in vivo cell therapy; CAR-T; acquisition; autoimmune disease; gene therapy; manufacturing; scalability; Bristol Myers Squibb; Gilead; AbbVie; AstraZeneca
Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended
Compugen; third quarter 2025; earnings beat; clinical-stage immunotherapy; revenue; net loss; cash runway; clinical trials; COM701; COM503 (GS-0321); rilvegostomig; AstraZeneca; Gilead
Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market
Merck; PCSK9 inhibitor; enlicitide; oral cholesterol pill; AstraZeneca; CORALreef trial; LDL-C reduction; AHA 2025; FDA approval; cardiovascular disease
AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial
AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile
White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations
most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca
AstraZeneca Reaches Drug Pricing Deal with White House, Becomes Second Pharma to Do So
AstraZeneca; White House; drug pricing; Medicaid; TrumpRx; most-favored-nation pricing; tariffs; Pfizer; drug discounts
AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025
AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates
AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer
Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02